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 Vitamin D metabolites are relatively 
hydrophobic and circulate bound to pro-
teins, primarily to the vitamin D-binding 
protein (DBP), and to a lesser extent to 
albumin. DBP, molecular weight 58  kDa, 
has high affi  nity for the major circulating 
vitamin D metabolite 25-hydroxyvitamin 
D (25(OH)D), and a 10- to 100-fold lower 
affi  nity for the vitamin D hormone 1,25-
dihydroxyvitamin D (1,25(OH) 2 D). Nor-
mal circulating levels of 25(OH)D are 
20 – 80  ng / ml, whereas 1,25(OH) 2 D levels 
are about 1000 times lower at 25 – 65 pg / ml. 
DBP is present at high levels in the blood 
(4 – 10   m), more than 20 times higher 
than the combined concentrations of vita-
min D metabolites, and has a serum half-
life of 2.5 – 3 days. Th e affi  nities of vitamin 
D metabolites for albumin are lower, but 
because of the high concentrations of 
these proteins in the blood, more than 
99 % of the circulating vitamin D com-
pounds are protein bound. 1 
 Although approximately 85 % of circu-
lating 25(OH)D is bound by DBP, 15 % is 
less tightly bound by albumin, and less 
than 0.1 % circulates in the unbound state. 
Th at portion of 25(OH)D or 1,25(OH) 2 D 
not bound to DBP but circulating free or 
bound to albumin constitutes  ‘ bioavail-
able ’ vitamin D, which is the subject of 
investigation by Bhan and colleagues 
in this issue of  Kidney International . 2 
Th ey report on a select subset of patients 
from the Accelerated Mortality on Renal 
Replacement (ArMORR) study, a large 
prospective cohort study of incident 
hemodialysis patients in the United 
States. 2,3 
 When Bhan  et al. use DBP levels to 
calculate bioavailable 25(OH)D and 
1,25(OH) 2 D, they are able to demonstrate 
a relationship to serum calcium that is 
not present when total 25(OH)D and 
1,25(OH) 2 D levels are examined. 2 Even in 
healthy subjects, DBP levels vary widely 
(tenfold), leading to corresponding vari-
ations in total 25(OH)D and 1,25(OH) 2 D, 
but free levels of the hormone and its pre-
cursor remain relatively constant. Th is is 
consistent with our expansive knowledge 
that vitamin D and parathyroid hormone 
(PTH) are the major regulators of calcium 
homeostasis, and their roles persist into 
end-stage renal disease. In further support 
of the free hormone hypothesis, bioavail-
able 25(OH)D, but not total 25(OH)D, 
correlates with PTH. Th e authors found 
no relationship of bioavailable vitamin D 
levels to serum phosphorus, 2 echoing the 
results in the original ArMORR report 
that total 25(OH)D and 1,25(OH) 2 D lev-
els did not correlate with serum phospho-
rus, which is more tightly regulated by 
fi broblast growth factor-23. 3 
 There is abundant evidence that the 
small fractions of unbound or free vitamin 
D compounds are biologically active. Th e 
free hormone hypothesis was fi rst intro-
duced by Mendel as a working model for 
the movement of lipophilic steroid hor-
mones through cell membranes to bind to 
their intracellular receptors. 4 Th e carrier 
proteins are impermeable to the cell and 
function as a reservoir for the systemic 
delivery of the ligands. Entry of 25(OH)D 
and 1,25(OH) 2 D into cultured keratino-
cytes 5 and monocytes 6 is decreased in the 
presence of DBP or serum. On the other 
hand, the 22-oxa analog of 1,25(OH) 2 D 
(oxacalcitriol) has much lower DBP affi  n-
ity than 1,25(OH) 2 D and has greater 
access to target tissues  in vivo , but is 
cleared more rapidly. 7 Th ese and other 
fi ndings demonstrate two roles of DBP in 
vitamin D physiology: prolonging the cir-
culating half-lives of vitamin D metabo-
lites and limiting their access to target 
tissues. DBP-ablated mice have very low 
levels of total 25(OH)D and 1,25(OH) 2 D, 
but free levels of the metabolites are 
normal as evidenced by the absence of a 
vitamin D-defi cient phenotype. 8 
 More recently, DBP was found to 
maintain vitamin D levels through a rea-
bsorption mechanism in the proximal 
tubules. 9 Filtered DBP binds to megalin 
(LRP2) and is taken up by proximal tubu-
lar cells by endocytosis; the DBP is 
degraded, and its vitamin D cargo is 
either metabolized or released into the 
circulation ( Figure 1 ). Megalin-ablated 
mice become vitamin D deficient and 
rachitic because of loss of DBP and its 
bound vitamin D metabolites in the 
urine. While there is evidence that con-
version of 25(OH)D to 1,25(OH) 2 D is 
impaired in megalin-defi cient mice, DBP-
ablated mice produce suff icient 
1,25(OH) 2 D to maintain serum calcium 
and phosphate, indicating that uptake of 
free 25(OH)D at the basolateral surface 
of proximal tubular cells also occurs. 
Thus, the primary role of DBP in the 
endocytic pathway appears to be in the 
reabsorption of vitamin D metabolites. 
Not surprisingly, then, proteinuria results 
in losses of DBP and may contribute to 
vitamin D defi ciency. 
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 Circulating DBP is produced by the 
liver and cleared by the kidney. Its levels 
are increased by estrogens and pregnancy 
and decreased in patients with cirrhosis 
and nephrotic syndrome. On the basis of 
the equations used by Bhan  et al. to calcu-
late bioavailable D, if DBP is twofold 
lower, free 25(OH)D will be about twofold 
higher. In the study by Bhan  et al. , the 
mean DBP level in black dialysis patients 
was less than half that observed in white 
patients. 2 Five black patients had DBP lev-
els below the limit of detection for the 
assay. In two prior studies in healthy 
young adults and pregnant women, Bhan ’ s 
group also found black ethnicity associ-
ated with signifi cantly lower DBP levels, 10 
whereas at least one other group has 
reported no relationship of black ethnicity 
to lower DBP levels in healthy young 
women. 
 If DBP levels are routinely lower among 
blacks, then we are probably overestimat-
ing the degree and severity of vitamin D 
deficiency in the black population. In 
2007, the fi rst ArMORR study in 825 inci-
dent hemodialysis patients noted that 
25(OH)D levels were less than 30  ng / ml in 
78 % of patients and less than 10  ng / ml in 
18 % . 3 Women, blacks, and diabetics were 
particularly likely to be severely vitamin 
D defi cient. If DBP levels in the overall 
ArMORR cohort parallel the results from 
the Bhan report, 2,3 then bioavailable 
25(OH)D levels among black patients are 
likely not different from those among 
white patients. 
 Th e 2007 ArMORR study also noted 
1,25(OH) 2 D levels were also low ( ~ 80 % of 
patients had levels less than 20 pg / ml), 
and these levels were not infl uenced by 
sex, ethnicity, or diabetic status. 3 Low lev-
els of both 25(OH)D and 1,25(OH) 2 D 
correlated with increased 90-day mortal-
ity. However, patients treated with active 
vitamin D (calcitriol), as is commonly 
done for secondary hyperparathyroidism 
or hypocalcemia, did not have increased 
mortality despite low incident vitamin D 
levels. 3 Treatment with calcitriol will of 
course normalize 1,25(OH) 2 D levels and 
may account for this observation. The 
finding of a significant relationship 
between endogenous vitamin D levels, 
subsequent active vitamin D therapy, and 
survival strongly suggests but does not 
prove a causal role for vitamin D defi -
ciency in the high mortality observed in 
incident dialysis patients. 3 If bioavailable 
25(OH)D and 1,25(OH) 2 D have even 
stronger relationships to survival among 
dialysis patients, then the causal role for 
vitamin D in survival is strengthened even 
more. Use of active vitamin D may have 
salutary eff ects on bone by stimulating 
bone formation, and inhibiting osteoclast 
production. Conversely, there are legiti-
mate concerns that administration of 
active vitamin D could lead to adynamic 
bone disease via oversuppression of PTH, 
induce hypercalcemia, or promote vascu-
lar calcification. Clearly, randomized 
clinical trials are needed in this area. 
 Black dialysis patients have signifi cantly 
higher PTH levels than white patients, 
and therefore blacks are more likely to 
receive active vitamin D and more likely 
to receive larger doses. 11 Among patients 
treated with active vitamin D, lower DBP 
levels could result in higher bioavailability 
and greater PTH-suppressing eff ect, but 
also enhanced active vitamin D clearance. 
Th erefore, it is not clear whether lower 
DBP levels would enhance or impair the 
PTH-suppressing eff ects of administered 
active vitamin D. Further study is war-
ranted to examine the relationship of 
DBP levels to control of secondary hyper-
parathyroidism by active vitamin D. 
 Th e potential eff ects of variable serum 
DBP on total versus free vitamin D metab-
olite levels are an important consideration 
in examining associations between these 
metabolites and various biological end 
points. As Bhan and colleagues demon-
strate, the associations of bioavailable 
metabolites with calcium are signifi cantly 
stronger than those of total metabolites. 2 
While further observational studies of the 
relationship of vitamin D levels and 
active vitamin D to clinical end points will 
undoubtedly continue to appear, clinical 
trials are needed to test the hypotheses 
that vitamin D use improves clinical 
outcomes. 
 DISCLOSURE 
 DWC is a consultant and speaker for Abbott. 
AJB has research grants from Abbott and 
Chugai Pharmaceuticals. 
 REFERENCES 
 1 .  Bouillon  R .  The vitamin D binding protein DBP .  
 In: Feldman D, Pike JW, Adams JS (eds).  Vitamin D , 
 3rd edn  Academic Press: San Diego ,  2011 ,  pp  
 57 – 72 . 
 2 .  Bhan  I ,  Powe  CE ,  Berg  AH  et al.  Bioavailable vitamin 
D is more tightly linked to mineral metabolism 
than total vitamin D in incident hemodialysis 
patients .  Kidney Int  2012 ;  82 :  84 – 89 . 
 3 .  Wolf  M ,  Shah  A ,  Gutierrez  O  et al.  Vitamin D 
levels and early mortality among incident 
hemodialysis patients .  Kidney International  
 2007 ;  72 :  1004 – 1013 . 
 4 .  Mendel  CM .  The free hormone hypothesis: 
a physiologically based mathematical model . 
 Endocr Rev  1989 ;  10 :  232 – 274 . 
 5 .  Bikle  DD ,  Gee  E .  Free, and not total, 1,25-
dihydroxyvitamin D regulates 25-hydroxyvitamin 
D metabolism by keratinocytes .  Endocrinology 
 1989 ;  124 :  649 – 654 . 
 6 .  Chun  RF ,  Lauridsen  AL ,  Suon  L  et al.  Vitamin 
D-binding protein directs monocyte responses 
to 25-hydroxy- and 1,25-dihydroxyvitamin D .  
J Clin Endocrinol Metab  2010 ;  95 :  3368 – 3376 . 
 7 .  Brown  AJ ,  Finch  J ,  Grieff  M  et al.  The mechanism 
for the disparate actions of calcitriol and 22-
oxacalcitriol in the intestine .  Endocrinology  1993 ; 
 133 :  1158 – 1164 . 
 8 .  Safadi  FF ,  Thornton  P ,  Magiera  H  et al.  Osteopathy 
and resistance to vitamin D toxicity in mice null 
for vitamin D binding protein .  J Clin Invest  1999 ; 
 103 :  239 – 251 . 
1α-Hydroxylation Megalin
Endocytosis
Mitochondria
LysosomeSecretion
25(OH)D
1,25(OH)2D
1,25(OH)2D–DBP
1,25(OH)2D –DBP
25(OH)D–DBP
25(OH)D– DBPDBP
DBP
Renal
tubular
lumen
Interstitial fluid
 Figure 1  |  Schematic of a proximal tubular cell demonstrating the role of megalin located in 
the brush border membrane in reclaiming DBP and any 25(OH)D or 1,25(OH) 2 D bound to 
DBP. Heavy proteinuria can lead to substantial DBP losses and potentially contribute to vitamin D 
deficiency. DBP, vitamin D-binding protein; 1,25(OH) 2 D, 1,25-dihydroxyvitamin D; 25(OH)D, 
25-hydroxyvitamin D. 
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 Corin: a key protein of 
an adaptive renal mechanism 
to respond to salt variation ? 
 Richard  Bouley 1 
 The protease corin generates atrial natriuretic peptide and affects 
blood pressure and salt – water homeostasis. Under dietary salt 
challenge, corin knockout mice show blood pressure exacerbation 
and significant weight gain due to water and salt retention. This 
phenotype involves the epithelial sodium channel but is independent of 
the renin – angiotensin – aldosterone system. This suggests that corin has 
an important role in a new adaptive mechanism of the response 
to variations of salt in the diet. 
 Kidney International (2012)  32, 7 – 8.  doi: 10.1038/ki.2012.123 
 Wang  et al. 1 (this issue) show with simple 
experiments the role of corin in blood 
pressure adaptation to salt diet challenge 
and highlight the importance of this 
enzyme in the homeostatic regulation 
mechanism of blood pressure. 
 Corin is a transmembrane serine pro-
tease of the trypsin superfamily. Th is pro-
tease is abundant in atrial and ventricular 
cardiac myocytes. Corin was also detected 
in the kidney and uterus. Interestingly, 
soluble fragments of corin have been 
detected in human blood. The plasma 
corin concentration is reduced in the case 
of heart failure, but increased in hyperten-
sion of pregnancy. 2 Th e soluble corin pro-
teolytic activity  in vivo is still elusive, but 
 in vitro assays suggest that both active and 
inactive fragments of corin were generated 
either by the action of the metalloprotease 
or by corin autocleavage. 3 More work is 
needed to answer this question, but these 
observations support the idea that soluble 
corin concentration in the bloodstream 
might be a promising biomarker in 
diseases such as heart failure, and during 
salt-related hypertension or pregnancy. 
Corin mediates the cleavage of pro-atrial 
natriuretic peptide (Pro-ANP), an inactive 
hormone, to an active hormone, atrial 
natriuretic peptide (ANP). ANP reduces 
sodium and water reabsorption and plays 
a role in blood pressure homeostasis. 
 It is known that plasma ANP levels are 
elevated in mice on a high-salt diet and 
that the absence of ANP or its receptor 
leads to hypertension. It was not surpris-
ing, therefore, to fi nd that deletion of the 
corin gene in the knockout mouse ( Cor  – / –  ) 
causes hypertension and cardiac hypertro-
phy. In African Americans, polymor-
phisms in the corin gene are associated 
with high blood pressure and cardiac 
hypertrophy. Corin is not the fi rst protease 
identifi ed as playing a major role in blood 
pressure homeostasis. Thus, renin and 
angiotensin-converting enzyme have also 
been shown to be involved in the patho-
physiology of hypertension ( Figure 1 ). 
 Renin and angiotensin-converting 
enzyme produce the active fragment angio-
tensin II, which increases sodium reab-
sorption by the Na   +   / H   +   exchanger in 
proximal tubules, where most of the fi l-
tered sodium is reabsorbed. A second hor-
mone, aldosterone, plays a role in the fi ne 
tuning of sodium reabsorption. Aldoster-
one increases the reabsorption of sodium 
in the collecting ducts by its eff ect on the 
epithelial sodium channel (ENaC). In con-
trast to angiotensin II and aldosterone, 
ANP inhibits the reabsorption of sodium 
by ENaC in the collecting ducts. Further-
more, the localization of corin in the kid-
ney and its proximity to the site of action 
of ANP support the idea that corin might 
play an important physiological role in this 
organ ( Figure 1 ). 
 Wang  et al. 1 (this issue) show that a 13-
fold increase in sodium concentration did 
not aff ect blood pressure in normal mice. 
However, the same high-salt diet signifi -
cantly aff ects the already high blood pres-
sure observed in mice that do not express 
corin ( Cor  – / –  mice). Interestingly, previous 
studies using 26 times more sodium 
reported an increased blood pressure in 
both wild-type and  Cor  – / –  mice. 4 This 
observation suggests first that corin 
expression and its production of ANP can 
help to handle variations of salt without 
aff ecting any major regulatory pathways. 
Second, this mechanism can be overloaded 
in the presence of a signifi cant amount of 
sodium. Th e eff ect of a high-salt diet on 
the high blood pressure of  Cor  – / –  mice was 
observed 2 weeks aft er they were returned 
to a normal diet. Interestingly, during a 
high-salt diet, both plasma renin and 
aldosterone concentrations are reduced. 
Th is eff ect is observed in both wild-type 
and  Cor  – / –  mice and may represent an 
attempt to reduce sodium reabsorption. A 
similar reduction of renin and aldosterone 
is observed with a physiological dose of 
ANP. 5 In addition, the knockout mice that 
did not express ANP receptor type 1 
showed an increase in serum aldosterone. 6 
Th us, the reduced level of aldosterone in 
 Cor  – / –  mice is unexpected. Is it possible 
that ANP is produced in the adrenal 
gland? Yet, the mechanism by which aldos-
terone but not renin is reduced in  Cor  – / –  
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